LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

Search

CareDx Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

19.14 -0.57

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

18.89

Max

19.67

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-88M

-10M

Pardavimai

-1.9M

85M

P/E

Sektoriaus vid.

16.92

50.291

Pelnas, tenkantis vienai akcijai

0.1

Pelno marža

-12.225

Darbuotojai

644

EBITDA

-6.1M

-13M

Rekomendacijos

By TipRanks

Rekomendacijos

Neutralu

12 mėnesių prognozė

+30.82% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-07-30

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

44M

1.1B

Ankstesnė atidarymo kaina

19.71

Ankstesnė uždarymo kaina

19.14

Naujienos nuotaikos

By Acuity

75%

25%

354 / 380 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Neutral Evidence

CareDx Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-06-26 23:49; UTC

Uždarbis

Nike Sees Sales Decline Decelerating in 1Q as Turnaround Strategy Plays Out -- 2nd Update

2025-06-26 22:19; UTC

Įsigijimai, susijungimai, perėmimai

FTC Clears Alimentation Couche-Tard's $1.57 Billion GetGo Acquisition

2025-06-26 21:30; UTC

Uždarbis

Nike 4Q Profit, Revenue Slides as Turnaround Strategy Plays Out -- Update

2025-06-26 21:07; UTC

Uždarbis

Nike 4Q Profit, Revenue Slide as Turnaround Strategy Plays Out

2025-06-26 23:49; UTC

Rinkos pokalbiai

Nikkei May Rise as Fears About Middle East Conflict Ebb -- Market Talk

2025-06-26 23:39; UTC

Rinkos pokalbiai

Gold Edges Lower, Weighed by Stronger-Than-Expected U.S. Data -- Market Talk

2025-06-26 23:34; UTC

Įsigijimai, susijungimai, perėmimai

Wesfarmers: Lease Reset Provides Opportunity for Upgrades, Extensions

2025-06-26 23:33; UTC

Įsigijimai, susijungimai, perėmimai

Wesfarmers: 62 BWP-Owned Bunnings Sites Get Significantly Longer Leases

2025-06-26 23:32; UTC

Įsigijimai, susijungimai, perėmimai

Wesfarmers Will No Longer Receive Earnings From BWP Management

2025-06-26 23:32; UTC

Įsigijimai, susijungimai, perėmimai

Wesfarmers to Increase BWP Holding to 23.5% From 22.3%

2025-06-26 23:31; UTC

Įsigijimai, susijungimai, perėmimai

Wesfarmers: New BWP Units Priced at 9.2% Premium to Last Close

2025-06-26 23:31; UTC

Įsigijimai, susijungimai, perėmimai

BWP to Pay A$100 Mln Cash, A$42.6 Mln in New Units

2025-06-26 23:30; UTC

Įsigijimai, susijungimai, perėmimai

Wesfarmers' Bunnings, BWP Trust to Extend and Vary Leases

2025-06-26 23:29; UTC

Įsigijimai, susijungimai, perėmimai

Wesfarmers to Sell BWP Management to BWP Trust for A$142.6M

2025-06-26 23:19; UTC

Įsigijimai, susijungimai, perėmimai

Andlauer Healthcare Group: Ontario Superior Court of Justice Issues Final Order Approving Sale to UPS

2025-06-26 22:06; UTC

Uždarbis

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

2025-06-26 21:15; UTC

Uždarbis

Nike 4Q Profit, Rev Slides as Turnaround Strategy Plays Out -- Update

2025-06-26 21:07; UTC

Įsigijimai, susijungimai, perėmimai

Couche-Tard: 35 Stores to Be Divested in Accordance With Regulatory Requirements >ATD.T

2025-06-26 21:07; UTC

Įsigijimai, susijungimai, perėmimai

Couche-Tard: GetGo Will Operate as Separate, Stand-Alone Business Unit, Maintain myPerks Loyalty Program >ATD.T

2025-06-26 21:07; UTC

Įsigijimai, susijungimai, perėmimai

Couche-Tard: Buyer Will be Approved by the FTC >ATD.T

2025-06-26 21:07; UTC

Uždarbis

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

2025-06-26 21:06; UTC

Įsigijimai, susijungimai, perėmimai

Couche-Tard Agreed to Sell 35 Sites, Including 34 Circle K Locations and One GetGo Property >ATD.T

2025-06-26 21:06; UTC

Įsigijimai, susijungimai, perėmimai

Couche-Tard: Transaction Is Expected to Close in the Coming Days >ATD.T

2025-06-26 21:06; UTC

Rinkos pokalbiai

Bank of Mexico Seen Likely to Slow Pace of Rate Cuts -- Market Talk

2025-06-26 21:05; UTC

Įsigijimai, susijungimai, perėmimai

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

2025-06-26 21:05; UTC

Įsigijimai, susijungimai, perėmimai

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

2025-06-26 20:52; UTC

Uždarbis

Nike 4Q Profit, Rev Slide as Turnaround Strategy Plays Out

2025-06-26 20:51; UTC

Uždarbis

Correct: Nike 4Q Net $211M, Not $200M >NKE

2025-06-26 20:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2025-06-26 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

Akcijų palyginimas

Kainos pokytis

CareDx Inc Prognozė

Kainos tikslas

By TipRanks

30.82% į viršų

12 mėnesių prognozė

Vidutinis 25 USD  30.82%

Aukščiausias 30 USD

Žemiausias 19 USD

Remiantis 5 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines CareDx Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

5 ratings

2

Pirkti

2

Laikyti

1

Parduoti

Techninis įvertinimas

By Trading Central

14.77 / 18.49Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Neutral Evidence

Vidutinės trukmės periodas

Strong Bearish Evidence

Ilgalaikis periodas

Weak Bearish Evidence

Rinkos nuotaikos

By Acuity

354 / 380 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Labai stiprus meškų rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę CareDx Inc

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.